Headline:
Revolutionary Russian anticancer vaccine shows promise in animal trials, targeting personalized treatments
Article:
Moscow, Russia – Scientists from the Sirius University of Science and Technology and the Gamaleya National Research Center of Epidemiology and Microbiology, along with leading oncologists from across Russia, have developed a groundbreaking vaccine against cancer that is currently undergoing trials in animals.
This novel vaccine aims to revolutionize cancer treatment by helping patients cure the disease, extend their lives, and minimize recurrence risks. The innovative approach behind this vaccine lies in its platform based on messenger RNA (mRNA), which trains the human immune system to recognize and attack cancerous cells.
In an interview with RT, Alexander Gintsburg, Director of the Gamaleya Center in Moscow, explained how the vaccine is designed to work. Once administered, the vaccine triggers the body’s immune system to produce cells that recognize and bind to tumor proteins, ultimately leading to the destruction of tumor cells and even metastasizing cells, without causing inflammation.
The upcoming vaccine is also set to be personalized, meaning it will be tailored to each patient’s specific cancer profile. Yury Sopot, one of the vaccine’s creators and Director of the Institute of Experimental Diagnostic and Tumor Therapy at the National Cancer Research Center N.N. Blokhin, told Lenta.ru that the vaccine could also serve as a therapeutic tool for patients who have undergone surgical tumor removal.
Regarding the vaccination schedule, patients will initially require a cycle of seven to eight injections, with subsequent periodic boosters to maintain the immune response and reduce the risk of relapse. While the vaccine is still in the early stages of development, scientists are optimistic about its potential.
Clinical trials in humans are expected to begin in the coming months, with ongoing animal testing indicating promising results. In June, Gintsburg announced that trials on melanoma-afflicted rats had shown significant tumor reduction in vaccinated animals compared to non-vaccinated peers.
Manufacturing the personalized vaccine is expected to take six to eight weeks per patient, with each dose costing approximately $3,000. However, Russian authorities aim to make the treatment accessible to all citizens free of charge.
Despite its promise, the vaccine may not entirely eliminate cancer in the near future. While it could potentially provide relief to patients with personalized treatments, not all cancer types may be susceptible to immunotherapy, and a universal preventative vaccine against the disease could remain elusive. Nonetheless, the prospect of a personalized cancer vaccine marks a notable advancement in the global fight against cancer.
